Genetic changes in nonepithelial ovarian cancer
暂无分享,去创建一个
[1] M. Pike,et al. Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. , 2013, Human molecular genetics.
[2] B. Benayoun,et al. Adult ovarian granulosa cell tumor transcriptomics: prevalence of FOXL2 target genes misregulation gives insights into the pathogenic mechanism of the p.Cys134Trp somatic mutation , 2013, Oncogene.
[3] M. Morgan,et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. , 2013, The Lancet. Oncology.
[4] R. Coleman,et al. Investigational agents in development for the treatment of ovarian cancer , 2013, Investigational New Drugs.
[5] S. Chu,et al. Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells. , 2013, Molecular endocrinology.
[6] J. Parma,et al. Leydig cell tumors in children: contrasting clinical, hormonal, anatomical, and molecular characteristics in boys and girls. , 2012, The Journal of pediatrics.
[7] A. Shelling,et al. The Transcriptional Targets of Mutant FOXL2 in Granulosa Cell Tumours , 2012, PloS one.
[8] J. Kigawa,et al. Clinical trials and future potential of targeted therapy for ovarian cancer , 2012, International Journal of Clinical Oncology.
[9] D. Armstrong,et al. Role of farletuzumab in epithelial ovarian carcinoma. , 2012, Current pharmaceutical design.
[10] S. Pangas. Bone morphogenetic protein signaling transcription factor (SMAD) function in granulosa cells , 2012, Molecular and Cellular Endocrinology.
[11] D. Bowtell,et al. The changing view of high-grade serous ovarian cancer. , 2012, Cancer research.
[12] W. Sellers,et al. Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations , 2012, Molecular Cancer Therapeutics.
[13] D. Gershenson. Treatment of ovarian cancer in young women. , 2012, Clinical obstetrics and gynecology.
[14] A. J. Hooten,et al. Associations between variants in KITLG, SPRY4, BAK1, and DMRT1 and pediatric germ cell tumors , 2012, Genes, chromosomes & cancer.
[15] B. Karlan,et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Steven J. M. Jones,et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. , 2012, The New England journal of medicine.
[17] P. Fuller,et al. Molecular pathogenesis of granulosa cell tumors of the ovary. , 2012, Endocrine reviews.
[18] K. Podratz,et al. Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: Brief report and review of the literature , 2012, The journal of obstetrics and gynaecology research.
[19] David Olmos,et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Bast,et al. Molecular approaches to personalizing management of ovarian cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] H. Earl,et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] I. Barshack,et al. FOXL2 C402G mutation detection using MALDI-TOF-MS in DNA extracted from Israeli granulosa cell tumors. , 2011, Gynecologic oncology.
[23] M. Hung,et al. Deciphering the role of forkhead transcription factors in cancer therapy. , 2011, Current drug targets.
[24] D. Rakheja,et al. Bone morphogenetic protein signalling activity distinguishes histological subsets of paediatric germ cell tumours. , 2011, International journal of andrology.
[25] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[26] R. Montironi,et al. KIT gene mutation and amplification in dysgerminoma of the ovary , 2011, Cancer.
[27] Kangseok Lee,et al. Differential apoptotic activities of wild-type FOXL2 and the adult-type granulosa cell tumor-associated mutant FOXL2 (C134W) , 2011, Oncogene.
[28] D. Huntsman,et al. FOXL2 Is a Sensitive and Specific Marker for Sex Cord-Stromal Tumors of the Ovary , 2011, The American journal of surgical pathology.
[29] M. Friedlander,et al. The Role of Hormonal Therapy in Gynecological Cancers-Current Status and Future Directions , 2011, International Journal of Gynecologic Cancer.
[30] Stephen L. Abrams,et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health , 2011, Oncotarget.
[31] Melissa J. Davis,et al. Nuclear Receptor Profiling of Ovarian Granulosa Cell Tumors , 2011, Hormones & cancer.
[32] A. Oza,et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] E. Simpson,et al. Aromatase Is a Direct Target of FOXL2: C134W in Granulosa Cell Tumors via a Single Highly Conserved Binding Site in the Ovarian Specific Promoter , 2010, PloS one.
[34] R. Broaddus,et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma , 2010, Cancer.
[35] Jason D. Wright,et al. Neoadjuvant bevacizumab in a granulosa cell tumor of the ovary: a case report. , 2010, Anticancer research.
[36] R. Butzow,et al. The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary , 2010, Modern Pathology.
[37] M. Friedlander,et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. , 2010, Gynecologic oncology.
[38] A. Mutirangura,et al. Targeted therapies for rare gynaecological cancers. , 2010, The Lancet. Oncology.
[39] Deborah Hughes,et al. Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer , 2010, Nature Genetics.
[40] N. Yoo,et al. Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers , 2010, The Journal of pathology.
[41] I Vergote,et al. The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. , 2010, Gynecologic oncology.
[42] Anton J. Enright,et al. Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. , 2010, Cancer research.
[43] A. Gartel. A new target for proteasome inhibitors: FoxM1 , 2010, Expert opinion on investigational drugs.
[44] R. Lovell-Badge,et al. Somatic Sex Reprogramming of Adult Ovaries to Testes by FOXL2 Ablation , 2009, Cell.
[45] Ryan D. Morin,et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. , 2009, The New England journal of medicine.
[46] S. Rubin,et al. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. , 2009, Gynecologic oncology.
[47] A. Sood,et al. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. , 2009, Gynecologic oncology.
[48] M. Greene,et al. A mini-review of familial ovarian germ cell tumors: an additional manifestation of the familial testicular germ cell tumor syndrome. , 2009, Cancer epidemiology.
[49] Deborah Hughes,et al. A genome-wide association study of testicular germ cell tumor , 2009, Nature Genetics.
[50] J. Baselga,et al. Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] S. Chu,et al. Proteasome Inhibition by Bortezomib Decreases Proliferation and Increases Apoptosis in Ovarian Granulosa Cell Tumors , 2009, Reproductive Sciences.
[52] P. Fuller,et al. Expression Status and Mutational Analysis of the PTEN and P13K Subunit Genes in Ovarian Granulosa Cell Tumors , 2009, International Journal of Gynecologic Cancer.
[53] S. Chu,et al. Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells. , 2009, Molecular endocrinology.
[54] E. Fridman,et al. Promising Effect of Aromatase Inhibitors on Recurrent Granulosa Cell Tumors , 2009, International Journal of Gynecologic Cancer.
[55] P. Mhawech-Fauceglia,et al. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. , 2008, Gynecologic oncology.
[56] Pier Paolo Pandolfi,et al. The PTEN–PI3K pathway: of feedbacks and cross-talks , 2008, Oncogene.
[57] B. Vanderhyden,et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] J. Sebolt-Leopold,et al. Advances in the Development of Cancer Therapeutics Directed against the RAS-Mitogen-Activated Protein Kinase Pathway , 2008, Clinical Cancer Research.
[59] Hans Skovgaard Poulsen,et al. Mechanisms for oncogenic activation of the epidermal growth factor receptor. , 2007, Cellular signalling.
[60] N. Colombo,et al. Management of ovarian stromal cell tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] M. Fellous,et al. Extinction of FOXL2 expression in aggressive ovarian granulosa cell tumors in children. , 2007, Fertility and sterility.
[62] R. Lothe,et al. Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers , 2007, Molecular Cancer.
[63] S. Modesitt,et al. Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases. , 2006, Gynecologic oncology.
[64] Phil G Knight,et al. TGF-beta superfamily members and ovarian follicle development. , 2006, Reproduction.
[65] C. Patte,et al. Activating mutations of the stimulatory g protein in juvenile ovarian granulosa cell tumors: a new prognostic factor? , 2006, The Journal of clinical endocrinology and metabolism.
[66] Liang Cheng,et al. Chromosome 12p abnormalities in dysgerminoma of the ovary: a FISH analysis , 2006, Modern Pathology.
[67] H. Denk,et al. Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study. , 2006, Gynecologic oncology.
[68] M. Fritsch,et al. Activation of Wnt/β-Catenin Signaling in Distinct Histologic Subtypes of Human Germ Cell Tumors , 2006 .
[69] M. Stratton,et al. Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. , 2006, Human molecular genetics.
[70] J. Amy,et al. GnRH antagonist in the adjuvant treatment of a recurrent ovarian granulosa cell tumor: a case report. , 2005, Gynecologic oncology.
[71] Liang Cheng,et al. Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications , 2005, Modern Pathology.
[72] C. Tzeng,et al. Molecular cytogenetics of ovarian granulosa cell tumors by comparative genomic hybridization. , 2005, Gynecologic oncology.
[73] J. Bell,et al. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. , 2005, Gynecologic oncology.
[74] Y. Nishi,et al. Transrepression of Estrogen Receptor Signaling by Nuclear Factor-B in Ovarian Granulosa Cells , 2004 .
[75] D. Schlessinger,et al. Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development. , 2004, Human molecular genetics.
[76] S. Chu,et al. Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours , 2004, Trends in Endocrinology & Metabolism.
[77] Mark P. de Caestecker,et al. The transforming growth factor-beta superfamily of receptors. , 2004, Cytokine & growth factor reviews.
[78] D. Schlessinger,et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome , 2001, Nature Genetics.
[79] G. Firestone,et al. Follicle-Stimulating hormone (FSH) stimulates phosphorylation and activation of protein kinase B (PKB/Akt) and serum and glucocorticoid-lnduced kinase (Sgk): evidence for A kinase-independent signaling by FSH in granulosa cells. , 2000, Molecular endocrinology.
[80] R. Lothe,et al. DNA copy number changes in malignant ovarian germ cell tumors. , 2000, Cancer research.
[81] S. Chu,et al. Comment on analysis of mutations in genes of the follicle-stimulating hormone receptor in ovarian granulosa cell tumors. , 1999, The Journal of clinical endocrinology and metabolism.
[82] H. Burger,et al. Inhibin subunit gene expression in ovarian cancer. , 1999, Gynecologic oncology.
[83] R. Scully,et al. Absence of mutations in the FSH receptor in ovarian granulosa cell tumors. , 1998, The Journal of clinical endocrinology and metabolism.
[84] R. Sutherland,et al. Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40. , 1998, Cancer research.
[85] N. Pavlidis,et al. Megestrol activity in recurrent adult type granulosa cell tumour of the ovary. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[86] R. Scully,et al. A mutation in the follicle-stimulating hormone receptor occurs frequently in human ovarian sex cord tumors. , 1997, The Journal of clinical endocrinology and metabolism.
[87] C. L. Edwards,et al. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. , 1996, The Journal of reproductive medicine.
[88] E. Kawasaki,et al. Two G protein oncogenes in human endocrine tumors. , 1990, Science.
[89] H. Burger,et al. Inhibin as a marker for granulosa-cell tumors. , 1989, The New England journal of medicine.
[90] A. Talerman. Germ cell tumors of the ovary. , 1987, Current opinion in obstetrics & gynecology.
[91] I. Vergote,et al. Dysgerminoma of the ovary in association with XY gonadal dysgenesis. , 1983, European journal of obstetrics, gynecology, and reproductive biology.
[92] M. Pike,et al. Testicular germ cell tumor susceptibility associated with the UCK 2 locus on chromosome 1 q 23 , 2013 .
[93] R. Butzow,et al. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors. , 2011, European journal of endocrinology.
[94] E. Petricoin,et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[95] J. Dungan. Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer , 2010 .
[96] J. Thigpen,et al. Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer , 2010 .
[97] P. G. Knight,et al. FOCUS ON TGF-? SIGNALLING: TGF-B SUPERFAMILY MEMBERS AND OVARIAN FOLLICLE DEVELOPMENT , 2006 .
[98] E. Eugster,et al. Premature thelarche and granulosa cell tumors: a search for FSH receptor and G5alpha activating mutations. , 2002, Journal of pediatric endocrinology & metabolism : JPEM.
[99] A. Bradley,et al. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. , 1992, Nature.